Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Buy” from Analysts

by · The Cerbat Gem

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) has been given a consensus rating of “Buy” by the five ratings firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $16.00.

A number of brokerages have weighed in on TENX. Leerink Partnrs raised Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. William Blair initiated coverage on Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating on the stock. Guggenheim initiated coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partners initiated coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, StockNews.com initiated coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating on the stock.

View Our Latest Stock Report on TENX

Tenax Therapeutics Stock Up 2.8 %

Shares of TENX opened at $5.06 on Tuesday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $33.44. The stock’s 50 day moving average is $4.13 and its two-hundred day moving average is $3.74.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $101,000. Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Finally, Stonepine Capital Management LLC acquired a new position in Tenax Therapeutics in the 3rd quarter valued at $173,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

(Get Free Report

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

See Also